MT027 not checked

Suzhou Maximum Bio-tech Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
5 active
5 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“MT027 will be injected intracerebroventricularly at a dose of 3×10\^7 cells on Day 1 \& Day 15 of each 28-day treatment cycle.”In the company’s words, NCT07386002 on ClinicalTrials.gov
Tested for
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Brain Metastases From Solid Tumors, Brain (Nervous System) Cancers, Brain and Central Nervous System Tumors, Brain Tumors, Advanced Malignant Solid Tumor, Malignant Pleural Effusion, Pleura Carcinoma and 4 more
Main trialPhase 2
“This is a Phase II trial to evaluate the safety, tolerability, efficacy, and PK/ pharmacodynamic profiles of MT027 injected via ICV in participants with recurrent or progressive IDH-wildtype glioblastoma (WHO 2021 CNS Grade 4), who have previously received standard of care (SOC) therapy. Each participant will undergo screening, treatment (receiving MT027 at a dose of 3×10\^7 cells), safety follow-up, and long-term follow-up periods. MT027 will be given via ICV injection on Day 1 \& Day 15 of the first 28-day cycle. If the participant does not experience any unacceptable toxicities and…”In the company’s words, NCT07386002 on ClinicalTrials.gov

Other drugs for Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

All 266 drugs for Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 2Not yet recruiting 13 Dec 2028 The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma
Phase 2Not yet recruiting 20 Dec 2029 The METAMAX Study: MT027 Allogeneic CAR-T for Brain Metastases From Advanced Solid Tumors
Phase 1Not yet recruiting 30 Dec 2025 Study of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors
Phase 1Recruiting May 2026 A Study of MT027 in Patients with Pleural Malignant Tumors
Phase 1Not yet recruiting 30 Jun 2026 Study of MT027 in Patients with Recurrent or Progressive High-grade Glioma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow MT027

Following is part of Solo: you see every change to MT027 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in